bezafibrate has been researched along with Glucose Intolerance in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aso, Y; Fukushima, M; Inukai, T; Momobayashi, A; Omori, K; Terasawa, T | 1 |
| Aoki, Y | 1 |
| Arcavi, L; Behar, S; Boyko, V; Caspi, A; Knobler, H; Reshef, N | 1 |
| Adler, Y; Behar, S; Boyko, V; Fisman, EZ; Goldenberg, I; Leor, J; Mandelzweig, L; Motro, M; Schwammenthal, E; Tenenbaum, A | 1 |
| Akabane, S; Inoue, I; Ishii, J; Katayama, S; Kawazu, S; Negishi, K; Suzuki, M; Takahashi, K | 1 |
| Fukamachi, I; Hashimoto, H; Kobayashi, J; Niihara, K; Saito, Y; Sasaki, N; Shirai, K; Takahashi, K; Tashiro, J; Yoshida, S | 1 |
1 review(s) available for bezafibrate and Glucose Intolerance
| Article | Year |
|---|---|
[Glucose intolerance in liver diseases].
Topics: Bezafibrate; Diabetes Mellitus; Glucose Intolerance; Humans; Hypolipidemic Agents; Insulin Resistance; Liver Diseases | 2002 |
3 trial(s) available for bezafibrate and Glucose Intolerance
| Article | Year |
|---|---|
High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study.
Topics: Aged; Bezafibrate; Blood Glucose; Coronary Disease; Diabetes Complications; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypolipidemic Agents; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Prognosis; Proportional Hazards Models | 2004 |
Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
Topics: Aged; Bezafibrate; Blood Glucose; Cholesterol; Comorbidity; Coronary Disease; Diabetes Mellitus, Type 2; Disease Progression; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypercholesterolemia; Hypolipidemic Agents; Incidence; Insulin; Life Tables; Male; Middle Aged; Myocardial Infarction; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2004 |
Improvement of glucose tolerance by bezafibrate in non-obese patients with hyperlipidemia and impaired glucose tolerance.
Topics: Bezafibrate; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Follow-Up Studies; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypercholesterolemia; Hyperlipidemias; Insulin; Male; Middle Aged; Pravastatin | 1994 |
2 other study(ies) available for bezafibrate and Glucose Intolerance
| Article | Year |
|---|---|
Bezafibrate, a peroxisome proliferator-activated receptor α agonist, decreases circulating CD14(+)CD16(+) monocytes in patients with type 2 diabetes.
Topics: Adult; Bezafibrate; Cross-Sectional Studies; Cytokines; Diabetes Mellitus, Type 2; Female; Gene Expression; Glucose Intolerance; GPI-Linked Proteins; Humans; Inflammation Mediators; Lipopolysaccharide Receptors; Male; Middle Aged; Monocytes; PPAR alpha; Receptors, IgG; RNA, Messenger; Translational Research, Biomedical | 2015 |
Effects of treatment with bezafibrate on lipoprotein lipase activity and mass in patients with hypertriglyceridemia.
Topics: Adult; Aged; Bezafibrate; Blood Glucose; Female; Glucose Intolerance; Humans; Hyperinsulinism; Hypertension; Hypertriglyceridemia; Immunoenzyme Techniques; Insulin; Lipase; Lipoprotein Lipase; Liver; Male; Middle Aged; Triglycerides | 1994 |